<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201013049018N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-07</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>"The effectiveness of dextrose prolotherapy in knee osteoarthritis"; "The effectiveness of genicular nerve block in knee osteoarthritis"</public_title>
      <acronym></acronym>
      <scientific_title>The comparison of the effectiveness of dextrose prolotherapy vs. genicular nerve block in reducing pain and improving function in patients with knee osteoarthritis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51683</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To match patients in the control and treatment groups, patients are randomly assigned to one of two treatment groups. The random allocation method in this study will be the permutation block randomization method, such that "A" represents the subject receiving the prolotherapy method, and "B" represents the subject who receives the genicular nerve block. This method is based on 15 blocks in 4 permutations, taking into account all possible quadruple permutations (AABB, ABAB, ABBA, BAAB, BBAA and BABA) and assigning zero to nine (according to a random number table) to each of these permutations (i.e. AABB Code 0, BABA Code 1, AABB Code 2, BBAA Code 3, BAAB Code 4, and ABBA Code 5 to 9). The method of using random table is that the 15 numbers from zero to nine (rows or columns) are randomly selected, and the assigned permutations to each number are written. (The order of placing permutations next to each other is left to right respectively) and how all 60 people will be assigned to two groups A and B, and so we will have two lists of 30 patients, including the two intervention and control groups, at random. For concealment, this method of random sequencing is given to another person who is unaware of the research process, and the questionnaires are completed by this person unaware of the division of groups, Blinding description: Participant: At this study, we are not able to blind the patient, because patients of both groups are aware of the type of the intervention.

Clinical caregiver: The caregiver is trained to complete the questionnaire and has no knowledge of the type of patient intervention.

Researcher:  at this study, we do not have the ability to blind the researcher, because the researcher does both studies himself and is aware of the type of intervention in each group.

The impact assessor: Completed questionnaires are given to a person who is not aware of the interventions performed and he/she is asked to determine the amount of pain reduction and functional increasement in each person according to the questionnaire.

Data analyzer: The questionnaires are finally given to a person to review the information after completing and collecting all the information. This person does not know any of the steps of the work and how to divide the intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Knee Osteoarthritis; Dextrose Prolotherapy; Genicular Nerve Block.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The group undergoing the block of three branches of the genicular sensory nerves (supramedial, supralateral and inframedial branches) in one session (common technique), using 1 cc of Razi company 70% alcohol under the guidance of ultrasound or fluoroscope and correcting lifestyle and doing proper knee exercises. Intervention 2: Control group: The group undergoing prolotherapy with Shahid Ghazi company 25% dextrose intraarticularly by needle (gauge 22) in 3 stages (one week apart) according to the usual protocol with the recommendation to follow the correct lifestyle and perform appropriate knee exercises.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All available data can be shared after making people unidentifiable

When:
start access period one year after publishing the results

To whom:
everyone can access to this information

Conditions:
if the information in this study helps to improve the science process

Where to obtain:
Dr. Mohammad Esmaeil ghorbani nejad
00989164168766
m_ghorbani1990@yahoo.com

How to obtain:
after sending the desired message, all authors of the study will be consulted all information will be sent within a maximum of the three weeks if permitted.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Esmaeil Ghorbani Nejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 82, Sepideh Tower, Baneshi Street, Parastar Blvd., Ehsan Square</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7184876856</zip>
        <telephone>+98 71 3639 6445</telephone>
        <email>m_ghorbani1990@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Esmaeil Ghorbani Nejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 82, Sepideh Tower, Baneshi Street, Parastar Blvd., Ehsan Square</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7184876856</zip>
        <telephone>+98 71 3639 6445</telephone>
        <email>m_ghorbani1990@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Existence of pain and other clinical signs of knee osteoarthritis and pain with a VAS score of at least 4 due to knee osteoarthritis during last month
Age between 45 to 70 years old
Absence of any periarticular disease around the target joint</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Diabetes Mellitus
Rheumatologically and collagen vascular disorders (eg; gout and lupus)
Radiculopathy
Nerve injuries and neuropathy
Brucellosis
BMI more than 42
Knee replacement on the affected side
History of trauma and joint fracture
Severe deformity of the lower extremities
Bleeding disorders
Inability to communicate
History of allergic reactions to the used drugs
History of intraarticular or periarticular injections at the affected joint in the last 3 months
History of significant liver, kidney and cardiopulmonary disorders
Pregnancy
Malignancy
Use of anticoagulants</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The group undergoing the block of three branches of the genicular sensory nerves (supramedial, supralateral and inframedial branches) in one session (common technique), using 1 cc of Razi company 70% alcohol under the guidance of ultrasound or fluoroscope and correcting lifestyle and doing proper knee exercises</i_keyword>
      <i_keyword>Control group: The group undergoing prolotherapy with Shahid Ghazi company 25% dextrose intraarticularly by needle (gauge 22) in 3 stages (one week apart) according to the usual protocol with the recommendation to follow the correct lifestyle and perform appropriate knee exercises</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain due to knee osteoarthritis. Timepoint: Before starting the intervention; 2, 4, 8, &amp;12 weeks later. Method of measurement: Visual analog scale; Western Ontario and McMaster Universities Arthritis Index; Oxford knee scale; Patient satisfaction.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Patient function. Timepoint: Before starting the intervention; 2, 4, 8, &amp;12 weeks later. Method of measurement: Visual analog scale.</sec_outcome>
      <sec_outcome>Patient function. Timepoint: Before starting the intervention; 2, 4, 8, &amp;12 weeks later. Method of measurement: Western Ontario and McMaster Universities Arthritis Index.</sec_outcome>
      <sec_outcome>Patient function. Timepoint: Before starting the intervention; 2, 4, 8, &amp;12 weeks later. Method of measurement: Oxford knee scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-08-17</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>No. 82, Sepideh Tower, Baneshi Street, Parastar Blvd., Ehsan Square Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
